Reactions Weekly

, Volume 1731, Issue 1, pp 5–5 | Cite as

Fasiglifam development terminated following phase III results

Clinical study


  1. Menon V, et al. Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial. Diabetes Care 41: 2603-2609, No. 12, Dec 2018. Available from: URL: CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations